Technical Articles

RAS is the most widely mutated oncogene in tumors, occurring in nearly 30% of human cancers. The RAS family includes three subtypes: KRAS, HRAS, and NRAS, with KRAS gene mutations accounting for approximately 85% of RAS family mutations.

The prognosis of pancreatic ductal adenocarcinoma is poor, primarily due to low diagnostic efficiency and strong tumor drug resistance. The activation of pancreatic stellate cells and the formation of dense stroma are key factors contributing to the aggressive nature of this tumor.

The KRAS gene is one of the oncogenes frequently mutated in tumors, with the G12D mutation widely present in various malignant tumors such as pancreatic cancer, colorectal cancer, and lung cancer.

The KRAS gene is one of the most common oncogenes in human cancers, frequently mutated in various solid tumors such as pancreatic cancer, colorectal cancer, and lung cancer.

The KRAS G12D mutation is one of the most common driver mutations in malignant tumors such as pancreatic cancer and colorectal cancer, with a significantly higher incidence than the KRAS G12C mutation.

The KRAS G12V mutation is one of the most common driver mutations in refractory tumors such as pancreatic cancer and lung cancer. Due to the intracellular localization of the KRAS protein, traditional antibody drugs struggle to directly target it, making this target a long-standing therapeutic challenge.

The KRAS gene, one of the first discovered human oncogenes, is frequently mutated in various malignancies such as pancreatic cancer, colorectal cancer, and lung cancer, driving tumor initiation and progression.

Pancreatic cancer, due to its hidden anatomical location, atypical early symptoms, rapid progression, and limited treatment options, has long ranked among the top in malignancy mortality rates, earning it the title "king of cancers."

Pancreatic cancer is one of the most malignant tumors in the digestive system, ranking among the leading causes of cancer-related deaths due to its difficulty in early diagnosis, rapid progression, and limited treatment options.

The KRAS gene is one of the most frequently mutated driver genes in tumors, playing a critical role in various malignancies such as colorectal cancer, pancreatic cancer, and non-small cell lung cancer.